Cargando…

Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients

Detalles Bibliográficos
Autores principales:	Tanaka, Masami, Yokoyama, Kaho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433394/ https://www.ncbi.nlm.nih.gov/pubmed/28607718 http://dx.doi.org/10.1177/2055217316632776

Ejemplares similares

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab
por: Sood, Arjun B., et al.
Publicado: (2016)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study
por: Riancho, Javier, et al.
Publicado: (2021)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
por: Dobson, Ruth, et al.
Publicado: (2022)

The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis
por: Fragoso, Yara Dadalti, et al.
Publicado: (2017)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
por: Castellazzi, Massimiliano, et al.
Publicado: (2016)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
por: Saida, Takahiko, et al.
Publicado: (2023)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_guusroql4r7vrkck3mb463lcvi